Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
8Customers
2Debt Items
0Related Chains
Source-Backed Evidence Depth
Kairos Pharma, Ltd. (KAPA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
15Total relationships
3Distinct source URLs
8High confidence
0.769Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Kairos Pharma, Ltd. Suppliers
Ticker
Name
Confidence
Evidence
CELYN-THERAPEUTICS-INC
CELYN-THERAPEUTICS-INC
92%
Pursuant to the Term Sheet, the Company agreed to acquire from Celyn 100% of the worldwide rights to CL-273, including development, manufacturing, commercialization, and related intellectual property…
PREVAIL-INFOWORKS-INC
PREVAIL-INFOWORKS-INC
92%
As part of the agreement, the Company was required to make an advance payment of $ 900 to Prevail before commencement of services and, at such time as we notify Prevail to engage their services relat…
CROSS-CURRENT-CAPITAL-LLC
CROSS-CURRENT-CAPITAL-LLC
90%
For the services rendered thereunder, the Company agreed to pay Cross Current $ 200 in cash and agreed to issue to the Advisor $ 500 of restricted shares of the Company’s common stock under the Compa…
TRACON-PHARMACEUTICALS-INC
TRACON-PHARMACEUTICALS-INC
90%
Pursuant to the Enviro-Tracon license agreement, Enviro paid Tracon an upfront fee of $100,000, and was obligated to pay Tracon an additional $500,000 upon its or its successor's completion of one or…
Kairos Pharma, Ltd. Customers
Ticker
Name
Confidence
Evidence
HELENA-GLOBAL-INVESTMENT-OPPORTUNITIES-I-LTD
HELENA-GLOBAL-INVESTMENT-OPPORTUNITIES-I-LTD
85%
the Company will have the right to issue and sell to Helena, from time to time, and Helena shall purchase from the Company, up to $ 30,000 of the Company’s shares of common stock
ANNUAL-REPORT-EMERGING-GROWTH-COMPANY
ANNUAL-REPORT-EMERGING-GROWTH-COMPANY
62%
ock, and amortization expense relating to the vendor advances was $2,170, with an unamortized balance of $845 as of December 31, 2025. Deferred Offering Costs Agreement with Helena Global Investment …
BRAMMER-BIO-MA-LLC
BRAMMER-BIO-MA-LLC
62%
xercise price of $1.40 per share, will be exercisable six months from issuance and will expire five and a half years from the issuance date. During the year ended December 31, 2025, the investor exer…
CELYN-THERAPEUTICS-INC
CELYN-THERAPEUTICS-INC
62%
xercise price of $1.40 per share, will be exercisable six months from issuance and will expire five and a half years from the issuance date. During the year ended December 31, 2025, the investor exer…
ENVIRO-THERAPEUTICS-INC
ENVIRO-THERAPEUTICS-INC
62%
ions and strategic collaborations, including licensing or acquiring complementary drug products, intellectual property rights, technologies, or businesses, as deemed appropriate to carry out our busi…
LONZA-SALES-AG
LONZA-SALES-AG
62%
xercise price of $1.40 per share, will be exercisable six months from issuance and will expire five and a half years from the issuance date. During the year ended December 31, 2025, the investor exer…
QUARTERLY-REPORT-EMERGING-GROWTH-COMPANY
QUARTERLY-REPORT-EMERGING-GROWTH-COMPANY
62%
xercise price of $1.40 per share, will be exercisable six months from issuance and will expire five and a half years from the issuance date. During the year ended December 31, 2025, the investor exer…
TRACON-PHARMACEUTICALS-INC
TRACON-PHARMACEUTICALS-INC
62%
er systems and those of our CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and…
Kairos Pharma, Ltd. Debt Obligations
Instrument
Description
Confidence
Evidence
KAPA-DEBT-10490
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-12-31.
KAPA-DEBT-10489
Warrants outstanding: 4.29
90%
xbrl warrant detail from xbrl 2024-12-31.
Kairos Pharma, Ltd. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Kairos Pharma, Ltd..
Kairos Pharma, Ltd. Ownership
Holder
Name
Confidence
Evidence
KAPA-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 11 tracked holders.
Kairos Pharma, Ltd. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
